The announcement of a public offering typically leads to short-term negative pressure on a company's stock price due to the dilution of existing shares. However, the capital raised can be beneficial for the company's growth and operations in the long term. The impact score is -1 due to the immediate dilutive effect, but the importance is not at the maximum because the amount raised is relatively small compared to larger biotech firms.